Specific carbohydrate diets, even modified, improve pediatric IBD symptoms Source: Disclosures: Suskind reports no relevant financial relationships. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
Back to Healio
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Back to Healio
Pediatric patients adhering to a specific carbohydrate diet or modified specific carbohydrate diet showed improved symptoms of their inflammatory bowel disease, according to a presentation at Crohn’s and Colitis Congress.
This article is a collaboration between MedPage Today and:
Treatment with oral ozanimod (Zeposia) reduced markers of intestinal inflammation among patients with moderately to severely active ulcerative colitis, confirming previously demonstrated clinical benefits.
Levels of fecal calprotectin declined by 68.7% at week 8 among patients receiving ozanimod, 0.5 mg per day, and by 70% for those receiving 1 mg per day, compared with 53.4% among those given placebo, according to William J. Sandborn, MD, of the University of California San Diego in La Jolla.
And at week 32, the corresponding decreases were 72.6% and 80.6%, compared with 42.3%, he reported during a poster session at the virtual Crohn s and Colitis Congress.
Date Time
Researchers develop wearable sweat sensor to predict IBD flare-ups
Bethesda, MD (Jan. 21, 2021) – The Crohn’s & Colitis Foundation and the American Gastroenterological Association (AGA) are committed to improving the lives of millions of Americans living with inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. That’s why we’ve partnered on the fourth annual Crohn’s & Colitis Congress®, taking place virtually Jan. 21 through 24, 2021. This annual meeting is an opportunity for IBD care providers to gather and learn about the latest advancements in IBD patient care.
/Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.
E-Mail
Bethesda, MD (Jan. 21, 2021) The Crohn s & Colitis Foundation and the American Gastroenterological Association (AGA) are committed to improving the lives of millions of Americans living with inflammatory bowel disease (IBD), including Crohn s disease and ulcerative colitis. That s why we ve partnered on the fourth annual Crohn s & Colitis Congress®, taking place virtually Jan. 21 through 24, 2021. This annual meeting is an opportunity for IBD care providers to gather and learn about the latest advancements in IBD patient care.
Below is a summary of three impactful studies being presented at the Crohn s & Colitis Congress. To speak with the study authors or review all 145 abstracts being presented, email media@gastro.org.
Share this article
Share this article
REHOVOT, Israel, Jan. 21, 2021 /PRNewswire/ Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), today announced it will be featured as a presenting company at the Crohn s & Colitis Congress® to be held from today January 21-24, 2021.
Prof. Yehuda Ringel, CSO of Biomica, will present
BMC322 - A rationally-designed live bacterial consortium based on microbiome functional genomic analysis for treatment of IBD on Saturday 23
rd January, 2021 at 2PM (EST).
The Crohn s & Colitis Congress is jointly organized by the American Crohn s & Colitis Foundation (CCFA) and the American Gastroenterological Association (AGA). The Congress connects IBD providers and researchers from around the world and will be held virtually this year.